{
    "clinical_study": {
        "@rank": "168080", 
        "arm_group": [
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.\nOptimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
            }, 
            {
                "arm_group_label": "Moxonidine group", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.\nOptimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis: Modulation of central nervous sympathetic activation by administration of\n      moxonidine, a centrally acting medication which decreases the sympathetic nervous system\n      activity, can lead to a decrease in atrial fibrillation recurrence after ablation treatment\n      with pulmonary vein isolation."
        }, 
        "brief_title": "Moxonidine for Prevention of Post-ablation AFib Recurrences", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Recurrence"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hypertensive patients with paroxysmal atrial fibrillation.\n\n          -  At least two documented episodes within the last 12 months (either self-terminating\n             within 7 days or cardioverted, medically or electrically, in less than 48 hours).\n\n          -  At least one episode should have been documented under treatment with a class Ic or\n             III antiarrhythmic drug.\n\n        Exclusion Criteria:\n\n          1. age <25 or >80 years\n\n          2. presence of atrial thrombus\n\n          3. left atrial volume index >55 ml/m2\n\n          4. hypersensitivity to moxonidine\n\n          5. sick sinus syndrome or sino-atrial block\n\n          6. 2nd or 3rd degree atrioventricular block\n\n          7. bradycardia (below 50 beats/minute at rest)\n\n          8. estimated glomerular filtration rate <40 ml/min/1.73 m2\n\n          9. history of angioneurotic oedema\n\n         10. heart failure symptoms OR impaired left ventricular function (EF <40%), even if\n             asymptomatic\n\n         11. stable or unstable angina pectoris\n\n         12. intermittent claudication or known peripheral artery disease\n\n         13. Parkinson's disease\n\n         14. epileptic disorders\n\n         15. glaucoma\n\n         16. history of depression\n\n         17. pregnancy or lactation\n\n         18. inability or unwillingness to adhere to standard treatment or to provide consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791699", 
            "org_study_id": "MOX.AFABL.9.5.2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Moxonidine group", 
                "intervention_name": "Moxonidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control group", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Moxonidine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "atrial fibrillation", 
            "paroxysmal", 
            "persistent", 
            "ablation", 
            "pulmonary vein isolation", 
            "recurrence"
        ], 
        "lastchanged_date": "May 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11527"
                    }, 
                    "name": "Athens General Hospital \"G. Gennimatas\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "10676"
                    }, 
                    "name": "Evangelismos General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Red Cross Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacologic Suppression of Central Sympathetic Activity for Prevention of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation (MOXAF)", 
        "other_outcome": {
            "description": "Moxonidine-related adverse effects will be monitored and recorded, focusing on xerostomia, headaches, sleep disorders, hypotension, orthostatic hypotension", 
            "measure": "Adverse effects", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Greece: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Any of the following, occuring after a 3-month blanking period, will be considered an AF recurrence:\nsymptomatic recurrence (AF/MRAT of any duration in ECGs performed in patients reporting symptoms of arrhythmia); the patients will be encouraged to visit the research site or any affiliated center to have an ECG performed at any time (24/7) they may feel symptoms of arrhythmia during the study follow-up\nAF/MRAT of at least 30 seconds in duration in 48-hour Holter recordings performed monthly\nAF/MRAT of any duration recorded in electrocardiograms performed during patient visits at the arrhythmia clinic, even if the patient is asymptomatic\n(AF=atrial fibrillation, MRAT=macro-reentrant atrial tachycardia)", 
            "measure": "AFib recurrence", 
            "safety_issue": "No", 
            "time_frame": "12 months+"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791699"
        }, 
        "responsible_party": {
            "investigator_affiliation": "G.Gennimatas General Hospital", 
            "investigator_full_name": "Spyridon Deftereos", 
            "investigator_title": "Director; Catheterization Laboratory and Cardiac Electrophysiology Laboratory", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The 17-item Hamilton Depression Rating Scale will be administered at baseline, and at the 3- and 6-month visits.", 
                "measure": "Depressive symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Any of the following, occuring within 2 months post-ablation, will be considered an early AF recurrence:\nsymptomatic recurrence (AF/MRAT of any duration in ECGs performed in patients reporting symptoms of arrhythmia); the patients will be encouraged to visit the research site or any affiliated center to have an ECG performed at any time (24/7) they may feel symptoms of arrhythmia during the study follow-up\nAF/MRAT of at least 30 seconds in duration in 48-hour Holter recordings performed monthly\nAF/MRAT of any duration recorded in electrocardiograms performed during patient visits at the arrhythmia clinic, even if the patient is asymptomatic", 
                "measure": "Early AFib recurrence", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "G.Gennimatas General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spyridon Deftereos", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}